Clinical efficacy data of capmatinib (Tourad) in the treatment of MET mutant lung cancer

Capmatinib (Capmatinib) is a selective MET tyrosine kinase inhibitor, mainly targeting MET exonsNSCLC) with an>14skipping mutation (METex14). METGene mutations can lead to continued activation of signaling pathways, thereby driving tumor cell proliferation and metastasis. Capmatinib precisely inhibits the MET pathway and blocks the growth signals of cancer cells, making it an important treatment option for patients with MET mutant lung cancer.

In clinical studies, capmatinib has demonstrated significant efficacy. GEOMETRY The results of the mono-1 study show that for patients with METex14 mutationsNSCLC who have not received previous systemic treatment, carbatidine The objective response rate (ORR) of nil reached approximately 68%, and the median duration of response was close to 12 months. For patients who have received previous treatment, the ORR is also above 40%, showing significant anti-tumor activity. These data indicate that capmatinib can provide more durable and stable clinical benefits in both first- and second-line treatments.

Capmatinib also performed outstandingly in terms of disease control rate and survival. The study found that the tumor volume of some patients was significantly reduced after treatment, and the progression-free survival (PFS) was significantly prolonged. What is particularly noteworthy is that capmatinib also has a certain effect on patients with brain metastases, showing its potential in controlling central nervous system lesions, which has important clinical significance for patients with advanced lung cancer.

Overall, the application of capmatinib in MET mutant non-small cell lung cancer brings new treatment hope to patients. Its clinical efficacy data not only confirms the importance of MET inhibition as a precision treatment direction, but also promotes the further development of targeted therapy in lung cancer. In the future, with the exploration of more real-world data and combination treatment options, capmatinib is expected to play a positive role in a larger range of patients.

Reference link:https://www.drugs.com